image: Taking place from August 25–29 at the University of Copenhagen, ARDD 2025 will bring together an unparalleled roster of talent: two Nobel laureates, eight of the top ten experts in longevity research, more than half of the top-ranked scientists in medicine and health recognized by the Nature Index 2025, and representatives from leading research institutions. Together, participants will delve into the latest breakthroughs in areas such as cell simulation, deep aging biomarkers, and cellular aging mechanisms, driving the field ever closer to achieving healthy longevity for all. During ARDD 2025, Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine, will join leaders from Eli Lilly, Biogen, and Fosun Pharma to discuss advances in longevity in the pharmaceutical industry, scheduled for 17:40–18:40 CET on August 26. He will also deliver a dedicated talk on the rational design of geroprotectors and clinical protocols at 19:00–19:20 CET on August 29. Meanwhile, Insilico's software and business development team will be actively engaged throughout the conference, with senior scientist Fedor Galkin presenting novel target discovery for IPF and aging research at 19:20–19:40 CET on August 27.
Credit: Insilico Medicine
Imagine a future where living longer is not only possible but comes with vitality and health. As the world grapples with an aging population, the race to unlock the secrets of longevity has become one of the most dynamic frontiers in science and technology.
What’s more covetable than making money? Probably Living longer
According to the United Nations' 2022 World Population Prospects report, the number of people aged 60 and above has surpassed 1 billion and will reach 2.1 billion by 2050, accounting for 22% of the world's population. This seismic shift introduces enormous challenges: increased rates of chronic diseases, rising healthcare costs, shifts in the labor force, and mounting pressure on social security systems.
Aging is no longer a distant scientific concept—it's a reality for us all.
In response, longevity is capturing the world's imagination—and investment. In 2024 alone, investment in longevity research soared to approximately $8.5 billion, a remarkable 220% increase from 2023. Major pharmaceutical companies have taken notice: Roche has committed $50 billion to R&D with a significant focus on aging, while Novartis is acquiring senotherapeutics startups. Across the globe, high-value partnerships are emerging, signaling that ageing research is moving from the fringes to the forefront, and rapidly becoming a core priority in the healthcare industry.
This global momentum is also reflected in the Aging Research and Drug Discovery (ARDD) conference. Founded in 2014, ARDD has grown into one of the world's most influential gatherings for aging science, renowned as a premier showcase for groundbreaking technologies and transformative results in longevity research. Interest continues to rise—underscored by the fact that this years' event sold out a month in advance.
Taking place from August 25–29 at the University of Copenhagen, ARDD 2025 will bring together an unparalleled roster of talent: two Nobel laureates, eight of the top ten experts in longevity research, more than half of the top-ranked scientists in medicine and health recognized by the Nature Index 2025, and representatives from leading research institutions. Together, participants will delve into the latest breakthroughs in areas such as cell simulation, deep aging biomarkers, and cellular aging mechanisms, driving the field ever closer to achieving healthy longevity for all.
Insilico Medicine: Driving Innovation at the Forefront of Longevity Research
As the founder and one of the earliest sponsors of ARDD, Insilico Medicine with the mission to extend health productive longevity has supported the conference for 11 years, consistently presenting cutting-edge, AI-driven research on aging and longevity. In previous years, the company has shared significant research achievements, including the novel aging clock, AI-based aging biomarker discovery, identification of dual-purpose targets in aging and disease, and the PreciousGPT series—a transformer-based life model that predicts biological changes across multiple tissues and species from birth to death.
Insilico has established a long-standing reputation for research and collaboration in the field of longevity. In 2016, the company published groundbreaking work in Nature Communications on In Silico Pathway Activation Network Decomposition Analysis (iPANDA), a gene expression-based AI method for biomarker development. By 2022, Insilico introduced PandaOmics—a target identification engine that integrates iPANDA with more than 20 advanced AI models—enabling the discovery of 145 potential therapeutic dual-purpose aging targets, with results published in Aging.
More significantly, Insilico's dual-purpose target strategy achieved first-in-class proof of concept for AI-driven discovery: Rentosertib (ISM001-055) demonstrated a dose-dependent efficacy trend against idiopathic pulmonary fibrosis (IPF) in a Phase IIa clinical trial. Notably, this investigational drug targets TNIK, a leading age-associated gene linked to multiple hallmarks of aging. In a recent study published in Aging, Insilico's researchers investigates the aging-related mechanisms in IPF using AI approaches.
Insilico's expertise in longevity research area also has been validated through collaborations with esteemed partners worldwide, including Taisho, Lineage, Juvenescence, and the Buck Institute in target identification and therapeutic development, as well as Life Extension and SRW in novel supplements.
ARDD 2025: Charting the Future of Healthy Longevity
During ARDD 2025, Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine, will join leaders from Eli Lilly, Biogen, and Fosun Pharma to discuss advances in longevity in the pharmaceutical industry, scheduled for 17:40–18:40 CET on August 26. He will also deliver a dedicated talk on the rational design of geroprotectors and clinical protocols at 19:00–19:20 CET on August 29. Meanwhile, Insilico's software and business development team will be actively engaged throughout the conference, with senior scientist Fedor Galkin presenting novel target discovery for IPF and aging research at 19:20–19:40 CET on August 27.
Together, we are committed to tackling the global problem of aging head-on with the latest AI technologies. We will continue to deepen human understanding of the biological mechanisms of aging and take the time to lead humanity one step closer to "healthy longevity" before translating them into therapies that will truly benefit humanity.
About Insilico Medicine
Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, medicine and science research using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com